Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Health Research Institutes, Taiwan
ClinicalTrials.gov Identifier:
NCT00201357
First received: September 13, 2005
Last updated: March 23, 2016
Last verified: March 2016

September 13, 2005
March 23, 2016
October 2002
July 2004   (final data collection date for primary outcome measure)
The primary objective is to determine the proportion of patients who have 50% decrease in PSA maintained for at least 4 weeks, in advanced hormone-refractory prostate cancer (HRPC) patients who receive thalidomide (100 mg BID). [ Time Frame: The primary objective is to determine the proportion of patients who have 50% decrease in PSA maintained for at least 4 weeks ] [ Designated as safety issue: Yes ]
The primary objective is to determine the proportion of patients who have 50% decrease in PSA maintained for at least 4 weeks
The primary objective is to determine the proportion of patients who have 50% decrease in PSA maintained for at least 4 weeks, in advanced hormone-refractory prostate cancer (HRPC) patients who receive thalidomide (100 mg BID).
Complete list of historical versions of study NCT00201357 on ClinicalTrials.gov Archive Site
Secondary objectives include the objective tumor response rate for measurable lesions, the median duration of tumor response, median time to disease progression and assessments of clinical benefits, quality of life, and safety profile. [ Time Frame: The primary objective is to determine the proportion of patients who have 50% decrease in PSA maintained for at least 4 weeks ] [ Designated as safety issue: Yes ]
The primary objective is to determine the proportion of patients who have the median duration of tumor response, median time to disease progression and assessments of clinical benefits, quality of life, and safety profil
Secondary objectives include the objective tumor response rate for measurable lesions, the median duration of tumor response, median time to disease progression and assessments of clinical benefits, quality of life, and safety profile.
Not Provided
Not Provided
 
An Open Trial to Assess the Efficacy and Safety of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer
An Open, Non-Comparative Trial to Assess the Efficacy and Safety of Oral Thalidomide (THADO) in Patientswith Hormone-Refractory Prostate Cancer-A PHASE II CLINICAL TRIAL
Trial objectives: The primary objective is to determine the proportion of patients who have 50% decrease in PSA maintained for at least 4 weeks, in advanced hormone-refractory prostate cancer (HRPC) patients who receive thalidomide (100 mg BID). Secondary objectives include the objective tumor response rate for measurable lesions, the median duration of tumor response, median time to disease progression and assessments of clinical benefits, quality of life, and safety profile.
  • Trial objectives: The primary objective is to determine the proportion of patients who have 50% decrease in PSA maintained for at least 4 weeks, in advanced hormone-refractory prostate cancer (HRPC) patients who receive thalidomide (100 mg BID). Secondary objectives include the objective tumor response rate for measurable lesions, the median duration of tumor response, median time to disease progression and assessments of clinical benefits, quality of life, and safety profile.
  • Number of patient : about 70 evaluable patients .Simon's optimal two-stage design will be used to allow early termination should sufficient evidence of non-effectiveness are collected. Thalidomide is considered non-effective if the proportion of PSA response is 14% or lower, and is worthy of further study if the proportion of response is 30% or higher. Controlling the risk for accepting thalidomide when it is non-effective to be at most 5% and the risk for rejecting thalidomide when it is effective to be at most 10%, this design calls for 26 patients at the first stage. If four or less PSA response is observed, then the study will be terminated. Otherwise, additional 44 patients will be entered at the second stage. The treatment will be rejected if a total of 14 or less PSA responses are observed out of 70 patients. This design has 70% chance of termination after the first stage if the true PSA response rate is 14% or lower. With 70 patients, the study will provide 95% assurance to claim that the difference between the estimated and true proportion will be within 11%.
  • Medication and Dose: Thalidomide (THADO 50mg/cap.) 100mg, BID.
  • Duration: Continue treatment until disease progression, unacceptable toxicity or when patient meets any off-study criteria.
  • Efficacy assessments: % of patients with 50% decrease in PSA maintained for at least 4 weeks,Objective tumor response Median duration of tumor response Median time to disease progression, Clinical benefits pain, performance status, weight
  • Quality of life (evaluated by the instruments of EORTC-QLQ-C30, FACT-prostate)Safety assessments:
  • Toxicity -Adverse Event -Laboratory Test
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Hormone-refractory Prostate Cancer
Drug: Thalidomide (THADO)
patients who receive thalidomide (100 mg BID).
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
July 2004
July 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 years of age or older.
  • Histologically or cytologically confirmed adenocarcinoma of prostate that is metastatic, hormone-refractory (confirmed by testing serum testosterone), and clinically progressive following at least one prior hormonal regimen.
  • Patients must have documented progression of disease on anti-androgen withdrawal, if the patient have documented progression on previous anti-androgen therapy.
  • Measurable (patient with measurable bi-dimensional disease) or evaluable disease (defined as the presence of a nonmeasurable abnormality on CT or on physical examination coupled with a PSA ³ 30).
  • Karnofsky performance status ³ 60%.6. Adequate bone marrow functions: Granulocyte count 1,000/mm3, Platelets 75,000/mm3, haemoglobin 8 g/dl.
  • Adequate renal and liver functions: Creatinine < 1.5 mg/dl, Bilirubin < 2 mg/dl, ALT/AST less than 2.5 times the upper limit of the reference range for the institute.
  • Patients with chemical or clinical hypothyroidism should have their thyroid replacement prior to starting study.
  • Patients must have recovered from the effect of recent surgery (at least 4 weeks apart), radiotherapy (at least 4 weeks apart).
  • Patients have ability to complete Quality of Life (QoL) questionnaires.
  • Patients must sign informed consent.

Exclusion Criteria:

  • Patients with advanced second primary malignancy.
  • Patients with brain metastases.
  • Patients with hypersensitivity to thalidomide.
  • History of myocardial infarction within past 6 months, uncontrolled congestive heart failure or angina pectoris.
  • Patients with orthostatic hypotension before therapy.
  • Patients with NCI CTC grade 3 or greater peripheral neuropathy of any cause that is clinically detectable.
  • Patients with active infection, including positive serology for HIV.
  • Patients who have received chemotherapy before for treatment of metastases of prostate cancer, or received other investigational agents or corticosteroids within 4 weeks prior to enrollment of study.
Male
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Taiwan
 
NCT00201357
T1802
Yes
No
Not Provided
National Health Research Institutes, Taiwan
National Health Research Institutes, Taiwan
Not Provided
Principal Investigator: Ruey-kuen Hsieh, M.D. Taiwan cooperative oncology group
National Health Research Institutes, Taiwan
March 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP